Elevating the Male Lupus Voice During Men’s Health Month
Elevating the Male Lupus Voice During Men’s Health Month
New Study Identifies Certain Gut Bacteria as Potential Drivers of Lupus Flares
New Study Identifies Certain Gut Bacteria as Potential Drivers of Lupus Flares
Toni Braxton Opens Up About Her Lupus Complications
Toni Braxton spoke recently about a “traumatic” heart procedure she underwent after she experienced a life-threatening lupus complication.
Article Credit: Lupus Foundation of America | lupus.org
New Findings in Lupus and Machine Learning
New research in machine learning finds four predictive lupus disease profiles.
Clinical Trial for New Lupus Treatment Opens in China
JW Therapeutics has received approval from the National Medical Products Administration of China to conduct a Phase 1 / 2 clinical trial of its CAR T-cell therapy, relmacabtagene autoleucel (relma-cel), for people with moderate to severe and/or treatment-resistant lupus. CAR T-cells are genetically altered T-cells that play a role in the immune response. Scientists create or engineer new cells called chimeric antigen receptors (CARs), and then introduce T-cells into them to create CAR-T cells.
Article Credit: Lupus Foundation of America | lupus.org
In People with Lupus, Age and Location Linked to Delayed Follow-Up After Hospitalization
March 30, 2023
Research shows younger people living with lupus and those living in rural or disadvantaged areas are less likely to have a follow-up appointment with their doctor shortly after they’ve been discharged from the hospital. One quarter of people with lupus are hospitalized every year, and one-third are re-hospitalized within 30 days, underscoring the importance of timely outpatient care.
Looking at data from 8,606 adults hospitalized with lupus on Medicare, researchers found that 35% lacked follow-up within 30 days overall. That follow-up rate is worse than the rate reported among people with other chronic diseases.
People with lupus who also exhibited the following characteristics were less likely to have a timely follow-up appointment after hospital discharge:
- More co-occurring illnesses
- A longer hospital length-of-stay
- Rural place of residency
- Greater neighborhood disadvantage
In the 65 years and older cohort, receiving timely follow-up care was associated with a 65% lower mortality rate in the month following hospital discharge, highlighting the tremendous value of outpatient treatment in this population in particular.
Regular preventative and follow-up care is critically important to living well with lupus, yet many struggle to get the medical support they need. Learn more about barriers to lupus diagnosis and care.
Article Credit: Lupus Foundation of America | lupus.org
Organ Damage Associated with Worse Cognitive Performance in People with Lupus
March 6, 2023
In a new study, organ damage was associated with worse cognitive performance in people with lupus. Cognitive dysfunction (CD) or “brain fog ” is a functional impairment whereby an individual exhibits deficits in attention, learning (verbal and nonverbal), memory (short-term and working), problem solving, motor (physical) function, processing speed, visual and auditory processing. At some point during their lives, 70-80% of people with lupus experience brain fog.
Researchers examined the disease and treatment records of 89 people with lupus. They found that organ damage was consistently associated with CD, and resulted in poorer performance in three of seven tests traditionally given to assess cognition. The researchers examined other markers of disease activity, blood test results, and genetic involvement for possible association to CD and none were found. CD can occur in people with lupus who do not exhibit high disease activity at a given point in time. Cognitive screening is important as prevalence of CD was identified by formal testing in only 8% of the group.
One of the study authors, Eric Morand, MBBS, PhD, Monash University, received the Lupus Foundation of America’s 2022 Evelyn V. Hess Award. Learn more about lupus and brain fog.
Article Credit: Lupus Foundation of America | lupus.org
New Study Found People with Lupus Have Unique Oral Bacteria
February 23, 2022
In a new study, researchers found people with lupus have a unique mix of oral bacteria, or “microbiome,” that is correlated with disease activity. The oral microbiome is made up of a collection of more than 700 unique bacterial species, and disturbances in the microbiome have been linked to various inflammatory diseases. The findings from this study suggest that specific oral bacteria found in people with lupus could be used as new, non-invasive lupus biomarkers and may serve as a therapeutic target for exploring new treatment options.
The oral microbiome is a collection of bacteria that affects the progression of health and disease. To assess whether oral bacteria diversity is linked to lupus, researchers compared the characteristics of the oral microbiome in people with lupus against a healthy control group. They collected and examined tongue coating samples from 255 people with lupus and 280 controls. Compared to the people without lupus, people with lupus had significantly more diverse oral bacteria present on their tongues. Furthermore, people with lupus had higher and lower levels of certain types of bacteria that were linked to greater disease activity.
These findings suggest people with lupus have a unique oral microbiome, which could promote new methods of lupus diagnosis and monitoring. While more research is needed to fully understand the relationship between lupus and the oral microbiome, these findings will help guide future studies. Learn more about oral health issues with lupus.
Article Credit: Lupus Foundation of America | lupus.org
New Investigational Drug for Systemic and Cutaneous Lupus Advancing to Phase I Clinical Trials
Ventus Therapeutics Inc. has announced the development of VENT-03, a potential first-in-class drug designed to target cGAS, a cell receptor linked to lupus and a broad range of other diseases including neuroinflammatory and neurodegenerative diseases. This will be the first drug of its kind to advance into clinical development, and it will enter its first Phase I trial cGAS is thought to be involved in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), and the latest news marks an exciting step forward in lupus drug development.
Last year, Ventus received a Lupus Research Program Idea Award from the U.S. Department of Defense (DoD) to study the cGAS inhibitor as a potential treatment for lupus. The Lupus Foundation of America’s (LFA) advocacy efforts and strong community of advocates led the fight in establishing the DoD Lupus Research Program in 2017, successfully advocating each year for continued funding of this critical program. To date, the program has provided more than $76 million to fund high-impact, high-quality studies to help find ways to diagnose and treat lupus more effectively.
Continue to follow the LFA for updates on VENT-03 and learn more about medications used to treat lupus.
Article Credit: Lupus Foundation of America | lupus.org